elafibranor
Selected indexed studies
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. (N Engl J Med, 2024) [PMID:37962077]
- Elafibranor. (, 2012) [PMID:39159277]
- Elafibranor: First Approval. (Drugs, 2024) [PMID:39110316]
_Worker-drafted node — pending editorial review._
Connections
elafibranor is a side effect of
Sources
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. (2024) pubmed
- Elafibranor. (2012) pubmed
- Elafibranor: First Approval. (2024) pubmed
- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. (2021) pubmed
- PMID:39899765 (2024) pubmed
- Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). (2020) pubmed
- Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial. (2026) pubmed
- Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. (2024) pubmed
- Elafibranor: A promising treatment for alcohol-associated liver disease? (2024) pubmed
- Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ. (2023) pubmed